Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesia  by El-Abiad, Nisreen M. et al.
ARTICLE IN PRESS
Respiratory Medicine (2007) 101, 2224–22260954-6111/$ - see fr
doi:10.1016/j.rmed.
Abbreviations: PC
binant human DNa
Pulmonary function
BAL, Bronchoalveola
Corresponding au
E-mail address: sCASE REPORT
Long-term use of nebulized human recombinant
DNase1 in two siblings with primary ciliary dyskinesia
Nisreen M. El-Abiada, Shelley Cliftonb, Samya Z. Nasrc,aFaculty of Medicine, Cairo University, Children’s Hospital, Cairo, Egypt
bDepartment of Pediatrics, Pediatric Pulmonary Function Laboratory, USA
cDivision of Pediatric Pulmonology, University of Michigan Medical Center, Ann Arbor, MI 48109-0212, USA
Received 12 April 2007; accepted 16 May 2007
Available online 29 June 2007KEYWORDS
Primary ciliary
dyskinesia;
rhDNase (dornase
alfa);
Pulmonary function
testingont matter & 2007
2007.05.014
D, Primary ciliary
se1 (dornase alfa
testing; FEV1, For
r lavage; DORV, D
thor. Tel.: +734 76
nasr@umich.edu (Summary
Primary ciliary dyskinesia (PCD) is characterized by ultra-structural defects of the cilia. In
this report, we describe the long-term use of nebulized dornase alfa in two siblings with
PCD. This is the first report of long-term use of dornase alfa in PCD.
& 2007 Published by Elsevier Ltd.Introduction
Primary ciliary dyskinesia (PCD) is characterized by ultra-
structural defects of the cilia.1 This leads to abnormal
function of the cilia in different organs, including the lungs.
PCD is an autosomal-recessive disease.2 Its prevalence is
estimated to be 1:20,000.1 The main presentation of PCD
includes chronic airway infection, inflammation, recurrent
pneumonia, bronchiectasis and sinusitis. If untreated, it can
lead to lung destruction.3Published by Elsevier Ltd.
dyskinesia; rhDNase, Recom-
); CF, Cystic fibrosis; PFT,
ced expiratory volume in 1 s;
ouble outlet right ventricle
4 4123; fax: +734 936 7635.
S.Z. Nasr).PCD, similar to cystic fibrosis (CF), is associated with a
neutrophil-dominant airway inflammation, which leads to
increased extra-cellular DNA, although the clinical course is
more benign than in CF.4 Similarities of the mucus properties
of PCD and CF were recently published.5
Recombinant human DNase1 [rhDNase, dornase alfa
(Pulmozymes, Genentech, Inc)] has been shown to reduce
sputum viscosity by degradation of extra-cellular DNA and
liquefaction of the thick mucus, improve pulmonary func-
tion (PFT) and reduce the number of pulmonary exacerba-
tions in CF.6,7
An early diagnosis of PCD can lead to appropriate
management, preservation of PFT and prevention of lung
damage.8,9 Currently, PCD patients are treated with chest
physiotherapy, antibiotics and bronchodilators.10 In this
report, we describe the long-term use of dornase alfa in
two siblings with PCD and worsening pulmonary symptoms
and PFTs despite conventional treatment. To our knowledge,
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Case reports
Case 1
Patient was 13 years of age, born at 35 weeks gestation. He
was diagnosed with situs inversus totalis, dextrocardia with
double outlet right ventricle (DORV), tricuspid insufficiency
and regurgitation as an infant. He underwent repair of DORV
at 9 months of age and tricuspid valvuloplasty at age 9
years. He developed persistent cough and wheezing during
the first year of life. An extensive workup revealed
Kartagner’s (PCD) syndrome. That was confirmed by elec-
tron microscopy of a nasal mucosal biopsy, which revealed
total absence of the dynein arms of the cilia. He was started
on bronchodilators, chest physiotherapy, frequent antibio-
tics and diuretics (for his cardiac disease).
At 26 months of age, in view of worsening respiratory
symptoms, a trial of nebulized dornase alfa (2.5mg once
daily) was initiated. Within few weeks, his respiratory
symptoms improved which lead to improvement in quality
of life.
On follow-up visits, he continued to do well with mild
intermittent cough and wheezing. At 6 years of age, a PFT
[Viasys Sensor Medics V6200 plethysmograph equipment
(V6200)] was performed. Percent predicted forced expira-
tory volume (FEV1) at 1 s was 92%. Dornase alfa was stopped
twice due to poor adherence at age 7 and 9 years. In both
occasions, the patient stated that he continued the rest of
the treatment plan. FEV1 decreased from 90% to 77% and
from 80% to 59%, respectively, within 4 months. Both
occasions were also associated with worsening respiratory
symptoms. Once dornase alfa was resumed, respiratory
symptoms improved and FEV1 increased to 81% and 87%,
respectively. The patient’s respiratory symptoms and FEV1
(89%) continued to be stable at 13 years of age with
continuation of dornase alfa.
Case 2
Patient was 17 years of age; he was born at full term. Before
6 years of age, he had chronic sinusitis and otorrhea. He
underwent functional endoscopic sinus surgery with several
revisions, adenoidectomy and tympanostomy tube place-
ment twice. He grew Pseudomonas aeruginosa from ear
discharge and was treated with frequent oral and intrave-
nous antibiotics. Immune deficiency and allergies were ruled
out. He was diagnosed with PCD at age 6 years after his
younger brother (case 1) was diagnosed. His ciliary structure
was similar to case 1. At diagnosis, he had no respiratory
symptoms, and FEV1 was 87%. He did not have Kartagener’s
syndrome or cardiac disease. He started to have respiratory
symptoms 6 months after diagnosis, and his FEV1 decreased
to 69%. He was started on bronchodilators, chest phy-
siotherapy and antibiotics. Dornase alfa was started
9 months later because of continuation of symptoms. At
that time, FEV1 was 78%. Respiratory symptoms gradually
improved and FEV1 increased to 89%, 7 months later.
At 9 years of age, dornase alfa was stopped. That wasfollowed by increase respiratory symptoms and decrease
FEV1 to 54%. After resumption of dornase alfa, his
respiratory symptoms improved and FEV1 increased to 83%.
He continued on his treatment plan including dornase alfa
with stabilization of respiratory symptoms and PFT. At 16
years of age, he had increased coughing, wheezing, poor
sleep pattern and shortness of breath. FEV1 decreased to
58%. That was due to poor adherence to dornase alfa and
depression. Attempts to improve adherence, including
coaching and counseling have not been successful.
The institutional review board exempted the two case
reports since they were retrospective in nature.Discussion
It has been established that inhaled dornase alfa improves
PFT and the well being of patients with CF.6,7 Since its
introduction, it was used to treat other chronic pulmonary
diseases.11–13 In these conditions, chronic inflammation
leads to recruitment and necrosis of neutrophils. DNA and
filamentous actin are released. They copolymerize to a rigid
secondary network increasing both sputum viscosity and
adhesiveness.14 Dornase alfa is both an effective mucolytic
agent, reducing the viscosity of secretions and mucokinetic
agent, improving cough clearance by reducing surface
adhesiveness.12
Two case reports documented the usefulness of the
short term use of dornase alfa in treating PCD.10,15 The first
report showed objective improvement in pulmonary func-
tion and marked improvements in both respiratory and
gastrointestinal symptoms from the short-term use of
nebulized dornase alfa. The patient was a 14-year-old girl
with Kartagener’s syndrome, who had intractable symptoms
and worsening PFT despite conventional treatment.10 The
second report documented rapid improvement of oxygena-
tion, lung function and symptoms in a 1-month-old infant,
shortly after starting dornase alfa when treatment with
antibiotics and physiotherapy had proven unsuccessful.15
Two more acute episodes over the next 7 months also
showed rapid clearing of symptoms with dornase alfa and
antibiotics.
This is the first report, to our knowledge, on the long-
term use of nebulized dornase alfa. It is also the first report
to demonstrate continued improvement with the use of this
medication in PCD. Both siblings’ respiratory symptoms and
PFT improved shortly after dornase alfa was started after
conventional treatment was unsuccessful. The improvement
continued for approximately 12 years. The long-term use of
dornase alfa in these patients was safe and not associated
with side effects. These findings are similar to those
reported in CF literature.6,16,17 In two occasions when
dornase alfa was stopped, significant deterioration of
respiratory symptoms and PFT occurred and improvement
resulted after the resumption of dornase alfa. This was
similar to the experience with intermittent use of dornase
alfa in CF.18
In conclusion, the long-term use of dornase alfa is
effective, well tolerated and safe in these patients with
PCD. A larger study is warranted to confirm the role of
dornase alfa in PCD management.
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